Terms: = Leukemia AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
224 results:
1. TCL1A-expressing B cells are critical for tertiary lymphoid structure formation and the prognosis of oral squamous cell carcinoma.
Xie W; Lu J; Chen Y; Wang X; Lu H; Li Q; Jin N; He J; Ou L; Ni J; Shen Y; Shao L
J Transl Med; 2024 May; 22(1):477. PubMed ID: 38764038
[TBL] [Abstract] [Full Text] [Related]
2. Pro-Inflammatory Activation Suppresses TRAIL-induced Apoptosis of Acute Myeloid leukemia Cells.
Kobyakova MI; Senotov AS; Krasnov KS; Lomovskaya YV; Odinokova IV; Kolotova AA; Ermakov AM; Zvyagina AI; Fadeeva IS; Fetisova EI; Akatov VS; Fadeev RS
Biochemistry (Mosc); 2024 Mar; 89(3):431-440. PubMed ID: 38648763
[TBL] [Abstract] [Full Text] [Related]
3. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
4. [Immune Reconstitution after BTKi treatment in Chronic Lymphocytic leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract] [Full Text] [Related]
5. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
[TBL] [Abstract] [Full Text] [Related]
6. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
7. In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
Brunner A; Thalhammer-Thurner GC; Willenbacher W; Haun M; Zelger BG; Willenbacher E
Ann Hematol; 2024 Feb; 103(2):553-563. PubMed ID: 37951851
[TBL] [Abstract] [Full Text] [Related]
8. treatment Refractoriness in Chronic Lymphocytic leukemia: Old and New Molecular Biomarkers.
Maher N; Mouhssine S; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373521
[TBL] [Abstract] [Full Text] [Related]
9. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract] [Full Text] [Related]
10. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract] [Full Text] [Related]
11. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid leukemia by Targeting XPO1/eIF4E/c-MYC Signaling.
Long H; Hou Y; Li J; Song C; Ge Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
[TBL] [Abstract] [Full Text] [Related]
12. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract] [Full Text] [Related]
13. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
[TBL] [Abstract] [Full Text] [Related]
14. Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study.
Flatt SB; Baillargeon A; McClintock C; Pudwell J; Velez MP
Reprod Health; 2023 Jan; 20(1):4. PubMed ID: 36593491
[TBL] [Abstract] [Full Text] [Related]
15. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
[TBL] [Abstract] [Full Text] [Related]
16. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract] [Full Text] [Related]
17. Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.
Karadaş N; Göktepe ŞŞÖ; Baş İ; Ece D; Özdemir HH; Balkan C; Kavaklı K; Aydinok Y; Karapinar DY
Int J Hematol; 2023 Mar; 117(3):446-455. PubMed ID: 36401784
[TBL] [Abstract] [Full Text] [Related]
18. [Study of cytogenetics and molecular biology in typical and atypical immunophenotypic chronic lymphocytic leukemia].
Jin HM; Qiao C; Zhao SS; Qiu HR; Chen X; Yang H; Zhu LY; Li JY; Wu YJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):469-474. PubMed ID: 35968589
[No Abstract] [Full Text] [Related]
19. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
[TBL] [Abstract] [Full Text] [Related]
20. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract] [Full Text] [Related]
[Next]
